FDA Approves Pivotal Cardiovascular Drug Vorapaxar

FDA Approves Pivotal Cardiovascular Drug Vorapaxar

Vorapaxar CAS 618385-01-6 Approved by the FDAOn May 8, 2014 the U.S. Food and Drug Administration approved the formidable cardiovascular drug Vorapaxar. Known as the brand name Zontivity, which is marketed by Merck, this pivotal medication has proven to be outstanding in clinical trials. In three short years of study Vorapaxar demonstrated its ability to successfully reduce the rate of death in over 17 percent of patients who had suffered cardiovascular trauma. Vorapaxar also lowered the risk of cardiovascular events and myocardial infractions in patients who were diagnosed with peripheral arterial disease. The current best in care treatment for patients who have survived traumatic cardiovascular events, such as a heart attack, is not effectual for every patient. Despite standard treatment with medications like Clopidogrel and aspirin, the need for adjunctive medications is growing increasingly common among the patients who have experienced cardiovascular trauma. The concomitant administration of Vorapaxar alongside aspirin and statins is an effective way to sizably lower the risk of additional cardiac events in this patient population.

Vorapaxar is a first-in-class inhibitor of the protease-activated receptor and is deemed to be an efficacious treatment option for patients who have endured a prior heart attack or have peripheral arterial disease. Data submitted to the FDA from Merck also offered encouraging statistics regarding a notable decrease in stroke risk for patients who were administered Vorapaxar {Zontivity}. At the conclusion of three years patients who were given Vorapaxar demonstrated a decline of stroke risk from 9.5 percent to 7.9 percent. While there is a black-box warning for Vorapaxar due to the potential for fatal bleeding episodes, the overall cardiac benefit of this potent drug is apparent for the almost 200,000 Americans who suffer from recurrent heart attacks after their first cardiovascular event.



Data disseminated from the TRA 2°P TIMI-50 study, which involved 499 patients overwhelmingly met the primary end point. Roughly 70 percent of patients enrolled in the aforementioned study had a prior myocardial infarction, and the primary goals from the study were to significantly reduce the risk of cardiovascular death and reduce repeated myocardial infarction. The patients in the TRA 2°P TIMI-50 study who were treated with 2.5 milligrams of Vorapaxar daily experienced a 13 percent reduction in the primary study end point. The study panel, which included experts from the Vanderbilt University School of Medicine, advised that the benefits of Vorapaxar outweighed the negative effect of excessive bleeding, but expressed that patients who had experienced a prior TIA or stroke should refrain from using this medication.

LGM Pharma provides Vorapaxar API, CAS# 618385-01-6 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service